Daniel R. Premkumar

University of Pittsburgh — United States

Medicine · Health Sciences

29h-index2.4kcitations108works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(35), Histone Deacetylase Inhibitors Research(31), Cancer, Hypoxia, and Metabolism(27), Cancer Mechanisms and Therapy(18), Protein Degradation and Inhibitors(13)

Publications107 total

TMET-39. DUAL TARGETING OF MAP KINASE SIGNALING AND METABOLISM IS A THERAPEUTIC VULNERABILITY IN PEDIATRIC DIFFUSE MIDLINE GLIOMAS
Neuro-Oncology·2024Open Access
CSIG-09. BEYOND SINGLE AGENTS: EXPLORING THE POTENTIAL OF ABEMACICLIB IN COMBINATION WITH PANOBINOSTAT FOR IMPROVED GLIOMA TREATMENT
Neuro-Oncology·2024Open Access
TMET-22. OVERCOMING RESISTANCE: PANOBINOSTAT SENSITIZES 2DG-RESISTANT PEDIATRIC HIGH-GRADE GLIOMAS WITH H3.3 K27M/G34R MUTATIONS TO APOPTOSIS
Neuro-Oncology·2024Open Access
Abstract 2037: Enhanced chemosensitivity to DNA-damaging agents in human high-grade glioma through 2-DG treatment
Cancer Research·2024
An ERK5-PFKFB3 axis regulates glycolysis and represents a therapeutic vulnerability in pediatric diffuse midline glioma
Cell Reports·2023· 15 citedOpen Access
DIPG-46. TARGETING THE METABOLIC ERK5-PFKFB3 AXIS IN PEDIATRIC DIFFUSE MIDLINE GLIOMA
Neuro-Oncology·2023· 1 citedOpen Access
Targeting mitochondrial energetics reverses panobinostat‐ and marizomib‐induced resistance in pediatric and adult high‐grade gliomas
Molecular Oncology·2023· 9 citedOpen Access
Supplementary File 3 from Targeting NAD<sup>+</sup> Biosynthesis Overcomes Panobinostat and Bortezomib-Induced Malignant Glioma Resistance
2023Open Access
Supplementary Figure 5 from Targeting NAD<sup>+</sup> Biosynthesis Overcomes Panobinostat and Bortezomib-Induced Malignant Glioma Resistance
2023Open Access
Supplementary Figure 4 from Targeting NAD<sup>+</sup> Biosynthesis Overcomes Panobinostat and Bortezomib-Induced Malignant Glioma Resistance
2023Open Access
Supplementary File 2 from Targeting NAD<sup>+</sup> Biosynthesis Overcomes Panobinostat and Bortezomib-Induced Malignant Glioma Resistance
2023Open Access
Supplementary Figures 1-6 from Bortezomib Sensitizes Malignant Human Glioma Cells to TRAIL, Mediated by Inhibition of the NF-κB Signaling Pathway
2023Open Access
Supplementary File 3 from Targeting NAD<sup>+</sup> Biosynthesis Overcomes Panobinostat and Bortezomib-Induced Malignant Glioma Resistance
2023Open Access
Data from Bortezomib Sensitizes Malignant Human Glioma Cells to TRAIL, Mediated by Inhibition of the NF-κB Signaling Pathway
2023Open Access
Supplementary File 1 from Targeting NAD<sup>+</sup> Biosynthesis Overcomes Panobinostat and Bortezomib-Induced Malignant Glioma Resistance
2023Open Access
Supplementary File 5 from Targeting NAD<sup>+</sup> Biosynthesis Overcomes Panobinostat and Bortezomib-Induced Malignant Glioma Resistance
2023Open Access
Supplementary Figure 7 from Targeting NAD<sup>+</sup> Biosynthesis Overcomes Panobinostat and Bortezomib-Induced Malignant Glioma Resistance
2023Open Access
Supplementary Figure 1 from YM-155 Potentiates the Effect of ABT-737 in Malignant Human Glioma Cells via Survivin and Mcl-1 Downregulation in an EGFR-Dependent Context
2023Open Access
Supplementary Figure Legends from Targeting NAD<sup>+</sup> Biosynthesis Overcomes Panobinostat and Bortezomib-Induced Malignant Glioma Resistance
2023Open Access
Supplementary File 1 from Targeting NAD<sup>+</sup> Biosynthesis Overcomes Panobinostat and Bortezomib-Induced Malignant Glioma Resistance
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Ian F. Pollack(26), Esther P. Jane(24), Raj N. Kalaria(9), Sameer Agnihotri(6), David Cohen(5), Brian Golbourn(5), Kimberly A. Foster(5), Robert P. Friedland(4), Rajesh N. Kalaria(4), Matthew Halbert(4), Stephanie M. Casillo(4), Steven J. Mullett(4), Taylor Gatesman(4), Stacy G. Wendell(4), Kelsey C. Bertrand(4), Stephen C. Mack(4), Nanduri R. Prabhakar(4), Philip Sutera(4), Jonathon Cavaleri(4), Alejandro Morales(4)